Summary & Overview
CPT 0084U: BLOODchip®ID CORE XT™ RBC Antigen Phenotyping
CPT code 0084U designates the BLOODchip®ID CORE XT™ proprietary laboratory test from Grifols Diagnostic Solutions Inc., a molecular assay that identifies red blood cell (RBC) antigen phenotypes across 10 blood groups and predicts 37 erythrocyte antigen phenotypes. The code matters nationally because precise RBC antigen typing supports transfusion safety, donor-recipient compatibility, and can reduce alloimmunization and transfusion complications in complex or sensitized patients. Laboratories, transfusion services, and blood centers use this specific PLA-coded test when standard serologic typing is insufficient or when molecular resolution is required.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the test’s clinical role and coding designation, payer coverage context, and the types of benchmarks and policy elements typically addressed for PLA molecular assays. The publication summarizes payment and coverage variation landscape, common billing modifiers and coding considerations, clinical indications that drive use of molecular RBC phenotyping, and where national policy updates or coding clarifications may affect billing practices. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0084U is a Proprietary Laboratory Analyses (PLA) code for the BLOODchip®ID CORE XT™ test from Grifols Diagnostic Solutions Inc. The test is a molecular-based assay that identifies blood donor and recipient red blood cell (RBC) antigen phenotypes to assist with blood compatibility determination. It detects markers across 10 blood groups and predicts 37 human erythrocyte antigen phenotypes.
-
Service type: Molecular-based laboratory assay for RBC antigen phenotyping
-
Typical site of service: Clinical laboratory or specialized blood bank laboratory
Clinical & Coding Specifications
Clinical Context
A 42-year-old woman with a history of multiple prior transfusions presents for elective surgery and requires pre-transfusion red blood cell compatibility testing. The transfusion medicine service orders a molecular antigen typing assay to determine donor and recipient erythrocyte antigen profiles when serologic typing is inconclusive or when extended antigen matching is needed (for example, in patients with alloantibodies, sickle cell disease, or chronically transfused patients). A phlebotomy specimen is collected and sent to the reference laboratory performing the BLOODchip®ID CORE XT™ assay. The laboratory performs DNA-based molecular testing to identify 37 human erythrocyte antigen phenotypes across 10 blood group systems and reports results to the transfusion service. Results guide selection of antigen-matched blood units and compatibility decisions, and are documented in the patient’s transfusion record and laboratory information system. Typical site of service: hospital laboratory or independent clinical diagnostic laboratory; service type: proprietary molecular laboratory assay (Proprietary Laboratory Analyses, PLA).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier reported | Use when no additional modifier applies to the claim |
11 |